Skip to main content
. Author manuscript; available in PMC: 2019 Jun 19.
Published in final edited form as: Immunity. 2018 May 29;48(6):1208–1219.e4. doi: 10.1016/j.immuni.2018.04.012

Figure 4. RANKL directly suppresses ILC3 function in vitro.

Figure 4

(A) GFP expression in Tnfrsf11aeGFP-Cre mice (n=10). Shaded histograms represent cells isolated from wild type control mice. (B) RANKL expression in ILC3 subsets and T cells (n=7). Shaded histograms represent RANKL antibody-stained Tnfsf11−/− cells. (C, D) IL-23 and IL-1β-elicited IL-17A and IL-22 production in primary sorted CCR6+ ILC3s pretreated with (C) soluble trimeric RANKL (n=7) or (D) a blocking antibody to RANKL (n=5). Also see Figures S2 and S3.